Dr. Victoria Hale is the Founder of Medicines360, a pharmaceutical scientist and global health social entrepreneur. Her passion is the development of important new medicines for all of humanity, with the specific goal to reduce health inequities. Dr. Hale is Founder & Chair Emeritus of One World Health, the first nonprofit pharmaceutical company in the US. She founded the company in 2000 and served as its first Chairman and CEO (2000-2008). Under her leadership the organization developed a new cure for visceral leishmaniasis, launched a novel approach to treat dehydrating diarrhea, and developed a platform technology to reduce the cost of malaria drugs by more than 10-fold. Dr. Hale established her expertise in all stages of biopharmaceutical drug development at the US Food and Drug Administration (FDA), and at Genentech. She earned her PhD in Pharmaceutical Chemistry from University of California San Francisco, where she presently maintains an Adjunct Associate Professorship in Biopharmaceutical Sciences. Her recent honors include being elected to membership in the Institute of Medicine of the US National Academies (2007), and being granted the MacArthur “Genius” Award (2006). She received the President’s Award of Distinction from the American Association of Pharmaceutical Scientists. She is internationally recognized as a senior social entrepreneur by the Skoll Foundation, Schwab Foundation, and Ashoka. The Economist named Hale the recipient of its Social and Economic Innovation Award (2005).
Dr. Michael Saag has spent his career treating and studying HIV/AIDS infection. Dr. Saag made seminal discoveries in the genetic evolution of HIV in vivo. He evaluated isolates of virus obtained from individual patients at different periods in time and cloned and molecularly characterized these isolates to determine the degree of diversity of co-existing viral variants and to describe their evolution over time (Nature, 1988). Within the clinic structure, he established a clinical trials unit, a data management center, and a Clinical Specimen Repository designed to support the activities of the newly established Center for AIDS Research at UAB. Since the establishment of the clinic, Dr. Saag has participated in many studies of antiretroviral therapy as well as novel treatments for opportunistic infections. He has published over 280 articles in peer reviewed journals. Dr. Saag has contributed over 50 chapters to medical textbooks, has served on the Editorial Board of AIDS Research and Human Retroviruses, co-Edited a textbook entitled AIDS Therapy and currently serves as an Editor of the Sanford Guide for Antimicrobial Agents and the Sanford HIV Guide. He recently served on the Board of Directors of the American Board of Internal Medicine (and as Chair of the Infectious Disease Subspecialty Board), has twice served as a member of the HIV Disease Committee of the Medical Knowledge Self-Assessment Program for the American College of Physicians, and has served recently on the NIH Office of AIDS Research Advisory Council. Dr. Saag currently serves on the International AIDS Society-USA Board of Directors, is President-elect of the HIV Medical Association, as a member of the HHS Guidelines Panel on Antiretroviral Therapy, and on numerous state, local, and national committees.